Celltrion clinches W110b drug substance supply deal from Teva
Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday it has secured a 110 billion-won ($83 million)
Celltrion clinches W110b drug substance supply deal from Teva
Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday it has secured a 110 billion-won ($83 million)